The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Alfresa Transfers Part of Shares of Vaccine-Related Subsidiary to 5 Drug Makers
November 6, 2014
- LEO Pharma to Develop JT’s JAK inhibitor for Skin Disorders Outside Japan
November 6, 2014
- Overseas Growth Boosts Combined Sales of Four Major Drug Makers
November 6, 2014
- Sawai Wins Livalo Trademark Suit
November 6, 2014
- Astellas, Dana-Farber Cut Deal on KRAS Inhibitor Development
November 6, 2014
- Astellas Ties Up with US Biotech on Therapies Modulating Unfolded Protein Response
November 6, 2014
- Terumo Seeks Japan Approval of Cell Sheets for Severe Heart Failure
November 6, 2014
- Takeda, Intra-Cellular Therapies End Collaboration on PDE1 Inhibitors
November 6, 2014
- US FDA Advisory Committee Backs Approval of Edoxaban: Daiichi Sankyo
November 6, 2014
- Kyowa Kirin Completes Construction of New Product Manufacturing Facility at Takasaki Plant
November 5, 2014
- Daiichi Sankyo Posts 30.6% Rise in First-Half Operating Profit, 1.7% in Revenue
November 4, 2014
- Sumitomo Dainippon Will Stick to FY2017 Earnings Targets despite BBI608 Setback: Pres.
November 4, 2014
- Astellas’s First-Half Sales Rise 9.3%, Operating Profit 61.8%
November 4, 2014
- Fujifilm to Take Majority Stake in Regenerative Medicine Startup J-TEC
November 4, 2014
- Bayer Seeks New Indications for Antibiotic Ciproxan
November 4, 2014
- AnGes MG to Initiate Multinational PIII Study of Collategene in Europe
November 4, 2014
- Takeda Aims for Consecutive Sales Growth through FY2022
October 31, 2014
- Sumitomo Dainippon’s Sales Down 1.7% on Drug Price Cuts in Japan
October 31, 2014
- Eisai Flounders in Japan, US Markets, Half-Year Profits Dive 60%
October 31, 2014
- Takeda Reports 2.8% Rise in First-Half Sales
October 31, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…